Amicus Therapeutics Inc (FOLD)vsRoyalty Pharma Plc (RPRX)
FOLD
Amicus Therapeutics Inc
$14.49
0.00%
HEALTHCARE · Cap: $4.55B
RPRX
Royalty Pharma Plc
$53.57
+3.32%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 285% more annual revenue ($2.44B vs $634.21M). RPRX leads profitability with a 33.9% profit margin vs -4.3%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
FOLD
Avoid30
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for FOLD.
Margin of Safety
-53.4%
Fair Value
$34.53
Current Price
$53.57
$19.04 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 23.7% year-over-year
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
Trading at 16.5x book value
Elevated debt levels
Weak financial health signals
ROE of -9.9% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : FOLD
The strongest argument for FOLD centers on Revenue Growth. Revenue growth of 23.7% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : FOLD
The primary concerns for FOLD are Price/Book, Debt/Equity, Piotroski F-Score. Debt-to-equity of 1.61 is elevated, increasing financial risk.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
FOLD profiles as a growth stock while RPRX is a mature play — different risk/reward profiles.
FOLD carries more volatility with a beta of 0.48 — expect wider price swings.
FOLD is growing revenue faster at 23.7% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 30/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amicus Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing and delivering drugs for people living with rare metabolic diseases. The company is headquartered in Philadelphia, Pennsylvania.
Visit Website →Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?